Vaxchora is a live attenuated recombinant V. cholerae O1 Inaba Vaccine Strain CVD 103-HgR, which is able to synthesize the immunogenic nontoxic B subunit of CT (encoded by the ctxB gene).
The V. cholerae vaccine strain produces an incomplete, nontoxic version of the cholera toxin it then replicates in the gastrointestinal tract.
Vaxchora is indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas.
Vaxchora is administered as a single oral dose at least 10 days before potential exposure to V. cholera.
Limitations of Use:
- The effectiveness of Vaxchora has not been established in persons living in cholera-affected areas.
- The effectiveness of Vaxchora has not been established in persons who have pre-existing immunity due to previous exposure to V. cholerae or receipt of a cholera vaccine.
- Vaxchora has not been shown to protect against disease caused by V. cholerae serogroup O139 or other non-O1 serogroups.